Display options
Cite
Makino I, Nakamura K, Sato Y, et al. Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders. Curr Ther Res Clin Exp. 2006;67(1):1-20doi: 10.1016/j.curtheres.2006.02.003.
Makino, I., Nakamura, K., Sato, Y., Sato, Y., Sezai, S., Ikeda, Y., Shinmura, W., Watahiki, H., Yamamoto, H., Hioki, Y., Suzuki, M., Kumada, T., Honda, T., Rikitoku, T., Hisanaga, Y., Fukui, H., Yamao, J., Kawasaki, H., Hosoda, A., Onji, M., Matsui, H., Sata, M., Torimura, T., Oho, K., Maekawa, R., Takagi, Y., Shakado, S., Nakayama, M., Gondo, K., Fukushima, H., Kusaba, T., Tsubouchi, H., Hayashi, K., Hori, T., Iida, Y., Yutoku, K., Maetani, N., Kubo, Y., & Miyata, Y. (2006). Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders. Current therapeutic research, clinical and experimental, 67(1), 1-20. https://doi.org/10.1016/j.curtheres.2006.02.003
Makino, Isao, et al. "Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders." Current therapeutic research, clinical and experimental vol. 67,1 (2006): 1-20. doi: https://doi.org/10.1016/j.curtheres.2006.02.003
Makino I, Nakamura K, Sato Y, Sato Y, Sezai S, Ikeda Y, Shinmura W, Watahiki H, Yamamoto H, Hioki Y, Suzuki M, Kumada T, Honda T, Rikitoku T, Hisanaga Y, Fukui H, Yamao J, Kawasaki H, Hosoda A, Onji M, Matsui H, Sata M, Torimura T, Oho K, Maekawa R, Takagi Y, Shakado S, Nakayama M, Gondo K, Fukushima H, Kusaba T, Tsubouchi H, Hayashi K, Hori T, Iida Y, Yutoku K, Maetani N, Kubo Y, Miyata Y. Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders. Curr Ther Res Clin Exp. 2006 Jan;67(1):1-20. doi: 10.1016/j.curtheres.2006.02.003. PMID: 24678081; PMCID: PMC3965972.
Copy Download .nbib Format: NLM
Share it on

Curr Ther Res Clin Exp. 2006 Jan;67(1):1-20. doi: 10.1016/j.curtheres.2006.02.003.

Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders.

Current therapeutic research, clinical and experimental

Isao Makino, Kimihide Nakamura, Yoichi Sato, Yuzuru Sato, Shuichi Sezai, Yusei Ikeda, Wahei Shinmura, Hajime Watahiki, Hideaki Yamamoto, Yayuki Hioki, Masao Suzuki, Takashi Kumada, Takashi Honda, Tomoo Rikitoku, Yasuhiro Hisanaga, Hiroshi Fukui, Junichi Yamao, Hironaka Kawasaki, Akihide Hosoda, Morikazu Onji, Hidetaka Matsui, Michio Sata, Takuji Torimura, Kazuhiko Oho, Ryuichiro Maekawa, Yoshiyuki Takagi, Satoshi Shakado, Masafumi Nakayama, Kazuhisa Gondo, Hirofumi Fukushima, Taku Kusaba, Hirohito Tsubouchi, Katsuhiro Hayashi, Takeshi Hori, Yozo Iida, Kouki Yutoku, Noboru Maetani, Yoshitsugu Kubo, Yoshifumi Miyata

Affiliations

  1. Second Department of Internal Medicine, Asahikawa Medical College, Hokkaido, Japan.
  2. Division of Gastroenterology, Kanto Medical Center NTT EC, Tokyo, Japan.
  3. Department of Internal Medicine, Tokyo- Kosei-nenkin Hospital, Tokyo, Japan.
  4. Department of Gastroenterology, Seirei Mikatahara General Hospital, Shizuoka, Japan.
  5. Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan.
  6. Third Department of Internal Medicine, Nora Medical University, Nora, Japan.
  7. Second Department of Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
  8. Third Department of Internal Medicine, Faculty of Medicine, Ehime University, Ehime, Japan.
  9. Second Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
  10. Department of Internal Medicine, Social Insurance Tagawa Hospital, Fukuoka, Japan.
  11. Department of Internal Medicine, Fukuoka Prefectural Yanagawa Hospital, Fukuoka, Japan.
  12. Department of Internal Medicine, Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka, Japan.
  13. Department of Internal Medicine, Miyazaki Medical College Hospital, Miyazaki, Japan.
  14. Department of Gastroenterology, Kokura Memorial Hospital, Fukuoka, Japan.
  15. Department of Internal Medicine, Chubu Hospital, Miyazaki, Japan.

PMID: 24678081 PMCID: PMC3965972 DOI: 10.1016/j.curtheres.2006.02.003

Abstract

BACKGROUND: Many Japanese patients with hepatic disorders confirmed on diagnostic imaging and coexisting upper gastrointestinal (GI) peptic lesions receive treatment with proton pump inhibitors. Some pharmacotherapies used to treat peptic ulcers have been associated with adverse drug reactions (ADRs), including elevated liver enzyme levels.

OBJECTIVE: The aim of this study was to determine the tolerability and effectiveness of rabeprazole sodium in treating peptic lesions in patients with coexisting hepatic disorders.

METHODS: This open-label, practice-based, postmarketing surveillance investigation was conducted at 15 centers across Japan. Male and female patients aged ≥18 years with peptic lesions confirmed on upper GI endoscopy and with underlying hepatic disease were enrolled. Patients were randomly assigned to receive rabeprazole 10 or 20 mg PO (tablet) QD after a meal for up to 8 weeks. Tolerability was assessed using monitoring of the incidence of ADRs determined by direct patient questioning, spontaneous reporting, and laboratory assessment. All patients who received at least 1 dose of study drug were included in the tolerability assessment. Effectiveness was assessed at baseline and study end using the rates of achievement of improvement on endoscopy, relief of subjective/objective symptoms (rates of improvement in epigastric pain and heartburn), and global improvement. The effectiveness analysis included all patients with complete data before and after treatment. Subanalyses were conducted to determine the effectiveness of drug by identification of the proportion of patients with coexisting hepatic disorders (cirrhosis, chronic hepatitis, and other hepatic diseases [eg, alcoholic hepatitis, fatty liver]) and by peptic lesion (gastric ulcer, duodenal ulcer, stomal ulcer, and reflux esophagitis) who achieved improvement.

RESULTS: A total of 114 patients were enrolled; 108 patients were included in the tolerability analysis (81 men, 27 women; mean age, 59.9 years; 10-mg dose, 90 patients; 20-mg dose, 18 patients) and 98 patients were included in the analysis of effectiveness. Twenty-one ADRs occurred in 11 (10.2%) patients. Serious ADRs occurred in 2 patients (elevated bilirubin level and hepatic encephalopathy, 1 patient each). Administration of rabeprazole was discontinued in 5 patients due to the occurrence of the following ADRs: constipation (1 patient); epigastric pain (1); dyslalia, disorientation, tremor, sleep disorder, and hepatic encephalopathy (1); diarrhea (1); and elevated alkaline phosphatase and y-glutamyl transpeptidase levels (1). On endoscopy, the proportion of patients achieving improvement with either dose was 30/33 (90.9%). The relief rates assessed using subjective symptoms were 47/55 (85.5%) and 47/56 (83.9%) for epigastric pain and heartburn, respectively. The proportion of patients achieving global improvement with either dose was 80/98 (81.6%) patients (49/62 [79.0%] for cirrhosis, 11/16 [68.8%] for chronic hepatitis, and 20/20 [100.0%] for other hepatic diseases [alcoholic hepatitis, fatty liver]).

CONCLUSION: In this study in Japanese patients with hepatic disorders, rabeprazole was well tolerated and appeared effective for the treatment of upper GI peptic lesions.

Keywords: chronic hepatitis; cirrhosis; duodenal ulcer; gastric ulcer; hepatic disorders; rabeprazole; reflux esophagitis; stomal ulcer; upper gastrointestinal lesions

References

  1. Gastroenterology. 1960 Mar;38:303-13 - PubMed
  2. Aliment Pharmacol Ther. 1999 Aug;13 Suppl 3:27-36 - PubMed
  3. Gut. 1986 Oct;27(10):1199-203 - PubMed
  4. Gastroenterology. 1987 Jul;93(1):135-40 - PubMed
  5. Pharmacotherapy. 1997 Jul-Aug;17(4):721-8 - PubMed
  6. Aliment Pharmacol Ther. 2003 Feb;17(3):343-51 - PubMed
  7. Am J Gastroenterol. 1990 Jan;85(1):34-7 - PubMed
  8. Nihon Rinsho. 1994 Jan;52(1):91-6 - PubMed
  9. Gastroenterology. 1990 Dec;99(6):1558-64 - PubMed
  10. Gut. 1985 Nov;26(11):1226-32 - PubMed
  11. J Gastroenterol Hepatol. 1989;4 Suppl 1:132-5 - PubMed
  12. Acta Hepatogastroenterol (Stuttg). 1976 Sep-Oct;23(5):351-9 - PubMed
  13. Gastroenterology. 1996 Jul;111(1):85-92 - PubMed
  14. Br J Clin Pharmacol. 1997 Feb;43(2):183-8 - PubMed
  15. Clin Ther. 1999 Apr;21(4):691-701 - PubMed
  16. Dig Dis Sci. 1996 Sep;41(9):1727-32 - PubMed
  17. J Gastroenterol Hepatol. 1989;4 Suppl 1:78-80 - PubMed

Publication Types